State Medicaid programs on board with Novartis’ Adakveo for sickle cell

Moving extraordinarily quickly, Medicaid programs in Florida and Alabama have approved coverage of Novartis’ (NYSE:NVS) sickle cell disease (SCD) med Adakveo (crizanlizumab-tmca), approved by the FDA only a month ago.

The selectin-inhibiting monoclonal antibody costs ~$113K per year.

https://seekingalpha.com/news/3527722-state-medicaid-programs-on-board-novartis-adakveo-for-scd